ECHELON-2 — brentuximab raises PTCL outcomes to new levels
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0163-3
Abstract: Lancet https://doi.org/10.1016/S0140-6736(18)32984-2 (2018) Diverse peripheral T cell lymphoma (PTCL) subtypes are usually treated using cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or similar regimens, with generally poor results. CD30 expression is common in many PTCL subtypes… read more here.
Keywords: chp; chop; treatment; brentuximab ... See more keywords
Brentuximab induced splinter nail haemorrhages in a patient with Sézary syndrome: a case report.
Sign Up to like & getrecommendations! Published in 2022 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15247
Abstract: Sézary syndrome is a systemic variant of cutaneous T-cell lymphoma (CTCL) characterized by erythroderma, lymphadenopathy, and circulating atypical lymphocytes (Sézary cells). It may present with nonspecific lesions on multiple digits. We describe an atypical case… read more here.
Keywords: splinter nail; induced splinter; brentuximab induced; brentuximab ... See more keywords
Considering the role of health economics in pyoderma gangrenosum and other dermatology research
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Dermatology"
DOI: 10.1111/bjd.15767
Abstract: tin in CD30 cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br J Dermatol 2017; 177:1503– 9. 5 Duvic M, Tetzlaff MT, Gangar P et al. Results of… read more here.
Keywords: lymphoma; dermatology; brentuximab; brentuximab vedotin ... See more keywords
Use of brentuximab vedotin as salvage therapy pre‐allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho‐proliferative disorders: a single centre experience
Sign Up to like & getrecommendations! Published in 2017 at "Internal Medicine Journal"
DOI: 10.1111/imj.13415
Abstract: The role of brentuximab peri‐allogeneic transplantation in patients with relapsed and/or refractory CD30 positive lymphomas remains poorly defined. read more here.
Keywords: relapsed refractory; transplantation; cd30 positive; brentuximab ... See more keywords